✨ Phage therapy news! We are happy to share that phages from PrecisionPhage were successfully used to treat recurrent sepsis caused by Pseudomonas aeruginosa. 🔗 Read the article here: https://lnkd.in/dW3VfmuY

Recently attended the 34th Malaysian Association of Clinical Biochemists Conference 2024 in collaboration with 2nd MyBiomed Symposium held on the 22nd and 23rd July 2024 as a delegates where I had showcased my abstract and poster on my final year project research titled as : Therapeutic Effects and Risks of Low Electromagnet Field (EMF) Exposure on Diabetic Wound Healing

Coconut water induces clinical remission in mild to moderate ulcerative colitis: double-blind placebo controlled trial, article still in press, but very interesting. DOI: https://lnkd.in/d_JQbzW7

#PracticeUpdate Clinical Question of the Week: Which therapy offered the most effective topical intervention for oral mucositis? Find the answer here: https://lnkd.in/g3FvZh35

Innovation is critical in the development of treatment options for immune-mediated diseases like psoriasis. With a wealth of advanced options already available, HCPs and patients have numerous choices, but unmet need remains. Our goal is to give more patients the opportunity to achieve durable, symptom-free remission. That means meeting or exceeding efficacy and safety standards alongside a mode of administration that best suits patient needs and goals. New data published in the New England Journal of Medicine provide insight into our investigational oral therapy for people living with moderate-to-severe psoriasis. https://bit.ly/487peT9 #Psoriasis #JNJImmunology

We’re pleased to share data recently published in the New England Journal of Medicine on patients with moderate-to-severe plaque psoriasis when treated with our investigational targeted oral peptide. These Phase 2b data reinforce our commitment to innovating treatment options for millions of patients living with moderate-to-severe plaque psoriasis who are eligible for but not receiving advanced treatments. Read more about the study here: https://bit.ly/3HYQB77 #NewData #Psoriasis #JNJImmunology

Psoriasis is a serious autoimmune disease that can have a tremendous impact on all aspects of life for people living with this condition. That’s why we’re so committed to advancing science to discover new treatment options that better meet patient needs and offer a combination of efficacy, tolerable safety profiles and desired routes of administration. New data published in the New England Journal of Medicine offer insight into an investigational targeted oral therapy that, if approved, could provide an important new option for many patients living with moderate-to-severe psoriasis.    https://bit.ly/487peT9     #Psoriasis #JNJImmunology 

On June 10th, Advanced Technology Company, in partnership with Stago havr hosted an event at the Symphony Hotel in #Kuwait. The focus was on the latest advancements and clinical applications of three vital diagnostic parameters: D-dimer, Anti-Xa, and Lupus Anticoagulant. The event attracted a distinguished audience, including doctors and senior Hematology lab professionals from the #Kuwait Ministry of Health, as well as physicians from private hospitals. This gathering provided an excellent platform for education, discussion, and networking, ultimately enhancing patient care practices. Key topics discussed included: - D-dimer: Its importance in diagnosing and managing thrombotic disorders. - Anti-Xa: Its role in monitoring anticoagulant therapy. - Lupus Anticoagulant: Its clinical significance in autoimmune conditions and blood clotting disorders. #InnovatingHealthcare

NEW SURVEY from the SSC Subcommittee on Physiological Anticoagulants and Thrombophilia: DOACs use in the treatment of antithrombin deficiency patients - the institutional approach. Please contribute your knowledge today: https://lnkd.in/ea9NDXjj Additionally, please contribute to other ongoing SSC PAT projects: --Current practice in thrombophilia testing: from phenotype to genotype: https://lnkd.in/gkMrzZqc --Biospecimens for Physiological Anticoagulants (Bio-PACS): https://lnkd.in/gGCQk8_F --Antithrombin Deficiency Registry: https://lnkd.in/eFDTgSn6 Vera Ignjatović

5. Conclusions aMMP-8, MPO, and PMN elastase eventually form a proteolytic and pro-oxidative tissue destruction cascade in periodontitis, potentially representing a therapeutic target. The active MMP-8 POCT identifies this periodontitis tissue destruction cascade in 5 min. The aMMP-8 POCT is the most efficient and precise discriminator between periodontal health and disease. The aMMP-8 POC test can be effectively used by dental professionals in their dental practices for the online and real-time diagnosis and monitoring of periodontal disease and to educate their patients and encourage good oral practices.